Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2018

  • ID: 4036988
  • Drug Pipelines
  • 220 pages
  • DelveInsight
until Dec 31st 2018
1 of 4


  • AdAlta
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • KBP Biosciences
  • Nitto BioPharma
  • ProMetic Life Sciences
  • MORE
“Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2018" report outlays comprehensive insights of present scenario and growth prospects across Idiopathic Pulmonary Fibrosis. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 65+ products along with 50+ companies involved.

Products covered by Phase
  • Phase III (Thrombomodulin Alfa by Asahi Kasei Pharma Corporation)
  • Phase II (BG-00011 by Biogen; Pamrevlumab by FibroGen; PBI4050 by ProMetic; GLPG1690 by Galapagos)
  • Phase I (HEC585 by HEC Pharm; AEOL 10150 by Aeolus Pharmaceuticals; C21by Vicore Pharma)
  • Pre-clinical (CG1011 by Therabron Therapeutics; GR-MD-02by Galectin Therapeutics) & Discovery (TGF-ß inhibitor by Pliant Therapeutics)
  • Inactive (Dormant and Discontinued)
Idiopathic Pulmonary Fibrosis - Understanding

Idiopathic Pulmonary Fibrosis (IPF) is a debilitating, chronic, fatal disease with an excess fibrous tissue called as fibrosis in the lungs. The idiopathic (unknown cause) character of the disease make it difficult to predict and treat in the initial stages. The irreversible damaging of lungs supporting frame work, fibrous tissue and interstitium effects the respiratory system functioning. As lungs are unable carry enough oxygen due to excessive scars, make it more difficult for a person to breathe. The disease progresses very rapidly and the median survival time is just two to three years.


The cause of IPF is idiopathic (unknown). Common risk factors responsible for IPF are:
  • Genetics: Genetics is the cause of about 20% of IPF. If more than one member has IPF then it is familial pulmonary fibrosis
  • Cigarette smoking: Approximately 75% of people are cigarette smokers with IPF
  • Acid reflux (Gastroesophageal Reflux Disease): Approximately 75% of people with IPF have symptoms of acid reflux or heartburn
  • Sex: Approximately 75% of patients with IPF are male
  • Age: Almost all patients with IPF are over the age of 50 years
  • Environmental factor: Working around dust or fumes moderately increase risk of developing the disease than non-exposed people
Overview of pipeline development activities for Idiopathic Pulmonary Fibrosis
  • Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details
  • Therapeutic segmentation of products for IPF
  • The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report:
  • Provides an overview of therapeutic pipeline activity for Idiopathic Pulmonary Fibrosis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Idiopathic Pulmonary Fibrosis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects for IPF
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Idiopathic Pulmonary Fibrosis to formulate effective R&D strategies
  • Assess challenges and opportunities that influence IPF
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Idiopathic Pulmonary Fibrosis to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Note: Product cover images may vary from those shown
2 of 4


  • AdAlta
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • KBP Biosciences
  • Nitto BioPharma
  • ProMetic Life Sciences
  • MORE
1. Report Introduction

2. Executive Summary

3. Idiopathic Pulmonary Fibrosis: Overview
3.1. Causes
3.2. Signs and symptoms
3.3. Diagnosis
3.4. Treatment
3.5. Epidemiology
3.6. Diagnosis

4. Pipeline Therapeutics (Active Products)

5. Comparative Analysis

6. Last Stage Products (Phase II)
6.1. Comparative Analysis
6.2. Thrombomodulin Alfa: Asahi Kasei Pharma
6.2.1. Product Description
6.2.2. Research and Development
6.2.3. Product Development Activities

7. Mid Stage Products (Phase II)
7.1. Comparative Analysis
7.2. GLPG1690 : Galapagos
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development
7.3. PBI4050 : ProMetic
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development
7.4. Pamrevlumab: FibroGen
7.4.1. Product Description
7.4.2. Research and Development
7.4.3. Product Development Activities
7.5. BG-00011 : Biogen
7.5.1. Product Description
7.5.2. Research and Development
7.5.3. Product Development Activities

8. Mid Stage Products (Phase II)
8.1. Comparative Analysis
8.2. HEC585: HEC Pharm
8.2.1. Product Description
8.2.2. Research and Development
8.2.3. Product Development
8.3. AEOL 10150: Aeolus Pharmaceuticals;
8.3.1. Product Description
8.3.2. Research and Development
8.3.3. Product Development
8.3.4. Research and Development
8.3.5. Product Development Activities
8.4. C21: Vicore Pharma
8.4.1. Product Description
8.4.2. Product Development Activities

9. Therapeutic Assessment: Active Products
9.1. Assessment by Stage and Product Type
9.2. Assessment by Route of Administration
9.3. Assessment by Stage and Route of Administration
9.4. Assessment by Molecule Type
9.5. Assessment by Stage and Molecule Type

10. Inactive Products
10.1. Comparative Analysis

11. Appendix
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • FibroStatin
  • AdAlta
  • Aeolus Pharmaceuticals
  • Allinky Biopharma
  • AnaMa
  • Aptuit LLC
  • Asahi Kasei Pharma
  • Beijing Tide Pharmaceutical
  • Biogen
  • Bioneer Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Chong Kun Dang Pharmaceutical
  • FibroGen
  • Five Prime Therapeutics
  • Galapagos NV
  • Galectin Therapeutics
  • GlaxoSmithKline
  • Glenmark
  • HEC Pharm
  • Histocell
  • iBio
  • Inventiva Pharma
  • Isarna Therapeutics
  • Kadmon Corporation
  • KBP Biosciences
  • Lung Therapeutics
  • MediciNova
  • Merck
  • miRagen Therapeutics
  • Moerae Matrix
  • MorphoSys AG
  • MSM Protein Technologies
  • Nitto BioPharma
  • Nuevolution
  • Nuformix
  • Olix Pharmaceuticals
  • Palobiofarma
  • Pharmaxis
  • Pliant Therapeutics
  • Promedior
  • ProMetic Life Sciences
  • Pulmatrix
  • Respira Therapeutics
  • Ribomi
  • Saje Pharma
  • Samumed
  • Sanofi
  • SPR Biosciences
  • StemMed
  • Therabron Therapeutics
  • Unity Biotechnology
  • Vicore Pharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown